<?xml version="1.0"?>
<ownershipDocument>
    <schemaVersion>X0201</schemaVersion>

    <documentType>4</documentType>
	<periodOfReport>2003-09-12</periodOfReport>
	<notSubjectToSection16>1</notSubjectToSection16>
    <issuer>
        <issuerCik>0000913610</issuerCik>
        <issuerName>SANGSTAT MEDICAL CORP</issuerName>
        <issuerTradingSymbol>SANG</issuerTradingSymbol>
	</issuer>
	<reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0000732485</rptOwnerCik>
            <rptOwnerName>GENZYME CORP</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>ONE KENDALL SQUARE</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>023191562</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
            <reportingOwnerRelationship>
			<isDirector>0</isDirector>
			<isOfficer>0</isOfficer>
			<isTenPercentOwner>1</isTenPercentOwner>
			<isOther>0</isOther>
		</reportingOwnerRelationship>
	</reportingOwner>
	<nonDerivativeTable>
		<nonDerivativeTransaction>
			<securityTitle>
				<value>SangStat Medical Corporation common stock (SANG)</value>
			</securityTitle>
			<transactionDate>
				<value>2003-09-12</value>
			</transactionDate>
			<deemedExecutionDate>
			</deemedExecutionDate>
			<transactionCoding>
				<transactionFormType>4</transactionFormType>
				<transactionCode>P</transactionCode>
				<equitySwapInvolved>0</equitySwapInvolved>
			</transactionCoding>
			<transactionAmounts>
				<transactionShares>
					<value>3153868</value>
				</transactionShares>
				<transactionPricePerShare>
					<value>22.50</value>
				</transactionPricePerShare>
				<transactionAcquiredDisposedCode>
					<value>A</value>
				</transactionAcquiredDisposedCode>
			</transactionAmounts>
			<postTransactionAmounts>
				<sharesOwnedFollowingTransaction>
					<value>26767514</value>
				</sharesOwnedFollowingTransaction>
			</postTransactionAmounts>
			<ownershipNature>
				<directOrIndirectOwnership>
					<value>D</value>
				</directOrIndirectOwnership>
				<natureOfOwnership>
					<value/>
				</natureOfOwnership>
			</ownershipNature>
		</nonDerivativeTransaction>
		<nonDerivativeTransaction>
			<securityTitle>
				<value>SangStat Medical Corporation common stock (SANG)</value>
			</securityTitle>
			<transactionDate>
				<value>2003-09-12</value>
			</transactionDate>
			<deemedExecutionDate>
			</deemedExecutionDate>
			<transactionCoding>
				<transactionFormType>4</transactionFormType>
				<transactionCode>U</transactionCode>
				<equitySwapInvolved>0</equitySwapInvolved>
			</transactionCoding>
			<transactionAmounts>
				<transactionShares>
					<value>26767514</value>
				</transactionShares>
				<transactionPricePerShare>
					<value>0</value>
				</transactionPricePerShare>
				<transactionAcquiredDisposedCode>
					<value>D</value>
				</transactionAcquiredDisposedCode>
			</transactionAmounts>
			<postTransactionAmounts>
				<sharesOwnedFollowingTransaction>
					<value>0</value>
					<footnoteId id="F1"/>
				</sharesOwnedFollowingTransaction>
			</postTransactionAmounts>
			<ownershipNature>
				<directOrIndirectOwnership>
					<value>D</value>
				</directOrIndirectOwnership>
				<natureOfOwnership>
					<value/>
				</natureOfOwnership>
			</ownershipNature>
		</nonDerivativeTransaction>
	</nonDerivativeTable>
	<footnotes>
		<footnote id="F1">Swift Starboard Corporation, a wholly-owned subsidiary of Genzyme Corporation, acquired the shares pursuant to a tender offer which expired at midnight, September 10, 2003.  The tendered shares were accepted for payment on September 11, 2003.  The consideration in the tender offer was $22.50 per share of SangStat stock, net to the seller in cash, without interest.  More then 90% of SangStat shares were tendered.  The remainder of the outstanding shares were acquired pursuant to a short-form merger which was effective September 12, 2003 in which Swift Starboard was merged with and into SangStat.</footnote>
	</footnotes>
	<remarks>
	</remarks>
	<ownerSignature>
		<signatureName>By: Michael S. Wyzga, Executive Vice President</signatureName>
		<signatureDate>2003-09-15</signatureDate>
	</ownerSignature>
</ownershipDocument>
[{"type": "4", "sequence": "1", "filename": "gen5.xml", "secsgml_size_bytes": 4399}]
X0201
4
2003-09-12
1
0000913610
SANGSTAT MEDICAL CORP
SANG
0000732485
GENZYME CORP
ONE KENDALL SQUARE
CAMBRIDGE
MA
023191562
0
0
1
0
SangStat Medical Corporation common stock (SANG)
2003-09-12
4
P
0
3153868
22.50
A
26767514
D
SangStat Medical Corporation common stock (SANG)
2003-09-12
4
U
0
26767514
0
D
0
D
Swift Starboard Corporation, a wholly-owned subsidiary of Genzyme Corporation, acquired the shares pursuant to a tender offer which expired at midnight, September 10, 2003.  The tendered shares were accepted for payment on September 11, 2003.  The consideration in the tender offer was $22.50 per share of SangStat stock, net to the seller in cash, without interest.  More then 90% of SangStat shares were tendered.  The remainder of the outstanding shares were acquired pursuant to a short-form merger which was effective September 12, 2003 in which Swift Starboard was merged with and into SangStat.
By: Michael S. Wyzga, Executive Vice President
2003-09-15